1 study found for:    A Phase Ii Study of Cyclophosphamide, Etoposide, Vincristine And Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Stage Ii, Iii And Iv Peripheral T-Cell Non-Hodgkin’s Lymphoma
Show Display Options
Rank Status Study
1 Active, not recruiting Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
Interventions: Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis

Indicates status has not been verified in more than two years